{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-120763","form_type":"8-K","ticker":"JAGX","cik":"0001585608","company_name":"Jaguar Health, Inc.","filed_at":"2025-05-15T23:59:59+00:00","discovered_at":"2026-05-14T18:02:48.902172+00:00","generated_at":"2026-05-21T05:00:30.843247+00:00","sec_items":["1.01","2.02","2.03","3.02","5.03","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"medium","headline":"Jaguar Health reduces royalty debt by $1.016M via equity exchanges; Q1 results released","bullets":["Issued 60,000 shares to Iliad for $466,200 reduction in October 2020 royalty interest.","Exchanged all 99.3822 Series J shares for Series L perpetual preferred stock with Streeterville.","Issued 22 Series L shares to Iliad for $550,000 royalty reduction; Series L pays 0%/10%/15% preferred return.","Q1 2025 earnings press released (financial details not provided in filing).","Company will seek stockholder approval to exceed Nasdaq exchange cap for Series L conversions."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-120763","json":"https://secwatch.observer/filing/0001193125-25-120763.json","markdown":"https://secwatch.observer/filing/0001193125-25-120763.md","text":"https://secwatch.observer/filing/0001193125-25-120763.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1585608/000119312525120763/0001193125-25-120763-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1585608/000119312525120763/d63848d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-21T05:00:30.843247+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}